FORA Capital’s Akebia Therapeutics AKBA Stock Holding History

FORA Capital’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,391	Closed	-$18K	–	861
2020 Q1	$18K	Buy	+2,391	New	+$18.6K	﹤0.01%	967

Other funds holding AKBA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FORA Capital's AKBA Position: Q2 2020 in Review

FORA Capital sold out of Akebia Therapeutics (AKBA) in Q2 2020, closing a stake of 2,391 shares — an estimated $18K sold.

FORA Capital first reported a position in AKBA in Q1 2020 and held it in 1 quarter. The position peaked at $18K in Q1 2020. 189 funds tracked by Wall St. Rank hold AKBA as of Q2 2020.

FORA Capital reported no remaining Akebia Therapeutics position as of Q2 2020 after selling out during the quarter.
FORA Capital sold 2,391 Akebia Therapeutics shares in Q2 2020, an estimated $18K.
FORA Capital first reported a position in Akebia Therapeutics in Q1 2020 and held it in 1 quarter.
FORA Capital's Akebia Therapeutics position peaked at $18K in Q1 2020.
189 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2020.

Based on FORA Capital's 13F filing for Q2 2020, filed 14 Aug 2020.